The fourth issue of the Novo Nordisk BlueSheet examines the disparity in diabetes prevention and care in racial and ethnic communities in the US, highlighting the Native American Communities which have one of the highest rates of diabetes in the country. Featured is an interview with Dr. Donald Warne, director of the Office of Native American Health at Sanford Health...
A new report by UnitedHealth Group’s Center for Health Reform & Modernization estimates that more than 50 percent of Americans could have diabetes or prediabetes by 2020 at a cost of $3.35 trillion over the next decade if current trends continue.
If this estimate is correct diabetes and prediabetes will account for an estimated 10 percent ...
Aetna, one of the leading diversified health care benefits companies in the US, serving approximately 35.4 million people, announced a pilot program aimed at improving the care of diabetic patients of Hispanic and African American descent. The new program is a year-long initiative that includes adding a bilingual diabetes educator, as well as introducing culturally appropriate materials to educate and engage patients in their health care. The pilot, which will be conducted in cooperation with the Medical Clinic of North Texas...
Data from a Phase 2b study suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug. Reata Pharmaceuticals and Abbott presented the new findings at the American Society of Nephrology (ASN) Renal Week Conference in Denver, Colorado....
It's Diabetes Awareness Month and Thanksgiving. Many of us have spent most of the month trying to make others aware of diabetes, and perhaps being extra aware of it ourselves. Now is a good time to stop and not only be aware of diabetes, but also to be grateful - not to diabetes of course, but for all the things we have to manage this disease.
Results of a new retrospective study of nearly 375,000 type 2 diabetes patients evaluating the incidence of events related to cardiovascular disease (CVD) and all-cause hospitalizations among initiators of BYETTA(R) (exenatide) injection compared to initiators of other commonly used diabetes medications were presented by Eli Lilly and Amylin Pharmaceuticals at the American Heart Association Scientific Sessions in Chicago...